Collaborations & Alliances

RXi Pharma and Thera Neuropharma Enter License Agreement

Will work on therapeutics for neurodegenerative diseases

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

RXi Pharmaceuticals and Thera Neuropharma have entered into an exclusive license agreement for RXi’s novel and proprietary sd-rxRNA platform to develop therapeutics for neurodegenerative diseases. Thera will be responsible for all research, development, manufacturing, regulatory and commercialization activities for the licensed products. The initial focus of the agreement will be on sd-rxRNA compounds targeting superoxide dismutase 1 (SOD1) for use in developing innovative treatments fo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters